Leena DasYoung - Guardant Health General Manager,Chief LUNAR Officer
| GH Stock | USD 16.16 0.90 5.28% |
Executive
Dr. Leena DasYoung is the General Manager, Chief LUNAR Officer of the company. Dr. DasYoung oversees all work applying Guardant Healths technology and database of more than 70, 000 clinical Guardant360 assay results, toward new applications in earlystage cancer, such as residual detection, recurrence monitoring, and early detection of cancer since 2017.
| Tenure | 7 years |
| Address | 3100 Hanover Street, Palo Alto, CA, United States, 94304 |
| Phone | 855 698 8887 |
| Web | https://guardanthealth.com |
Guardant Health Management Efficiency
The company has Return on Asset (ROA) of (0.1764) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1764. This is way below average. Likewise, it shows a return on total equity (ROE) of (4.3813) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.37. As of now, Guardant Health's Debt To Assets are increasing as compared to previous years. The Guardant Health's current Fixed Asset Turnover is estimated to increase to 2.51, while Total Assets are projected to decrease to under 1.4 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jerry Diffley | Natera Inc | N/A | |
| Ian Cooney | Caredx Inc | N/A | |
| Matthew MD | Castle Biosciences | N/A | |
| Stephane Mouradian | Personalis | N/A | |
| James Yee | Caredx Inc | 68 | |
| William Banyai | Twist Bioscience Corp | 69 | |
| Kristen RN | Castle Biosciences | 56 | |
| Tobin Juvenal | Castle Biosciences | 64 | |
| Josh DeFonzo | Caredx Inc | 34 | |
| Robert Schueren | Natera Inc | 62 | |
| Mena Farag | Illumina | N/A | |
| Karen Nelson | Thermo Fisher Scientific | N/A | |
| Pat Leckman | Illumina | 60 | |
| Bas Verhoef | Illumina | N/A | |
| Glenn Farrell | Myriad Genetics | N/A | |
| Robert Cook | Castle Biosciences | 52 | |
| Matthew Scalo | Myriad Genetics | N/A | |
| Michael Esq | Thermo Fisher Scientific | 62 | |
| Joydeep MBA | Illumina | 53 | |
| Ankur Dhingra | Agilent Technologies | N/A | |
| Scott Gleason | Myriad Genetics | 45 | |
Management Performance
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 |
Guardant Health Leadership Team
Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AmirAli Talasaz, President COO, Director | ||
| Richard Lanman, Chief Medical Officer | ||
| Marcel Roche, Vice President - Finance | ||
| Ian Clark, Lead Independent Director | ||
| Leena DasYoung, General Manager,Chief LUNAR Officer | ||
| John Saia, Chief Secretary | ||
| DEREK BERTOCCI, CFO | ||
| Terilyn Monroe, Chief Officer | ||
| Craig MD, Chief Officer | ||
| Andy Ament, VP Operations | ||
| Kumud Kalia, Chief Officer | ||
| Michael Bell, Chief Officer | ||
| Michael Wiley, Chief Legal Officer | ||
| Aaref Hilaly, Independent Director | ||
| Darl Moreland, Senior Quality | ||
| Jennifer Higgins, Vice Affairs | ||
| Dipchand Nishar, Independent Director | ||
| Christopher Freeman, Chief Officer | ||
| Helmy Eltoukhy, CoCEO CoFounder | ||
| Mark Jacobstein, Chief User Engagement Officer | ||
| Bahija Jallal, Director | ||
| Stanley Meresman, Independent Director | ||
| Lynn Lewis, IR Contact Officer | ||
| Darya Chudova, VP Technology | ||
| Samir Kaul, Independent Director |
Guardant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.85) % | ||||
| Operating Margin | (0.73) % | ||||
| Current Valuation | 2.15 B | ||||
| Shares Outstanding | 121.71 M | ||||
| Shares Owned By Insiders | 4.14 % | ||||
| Shares Owned By Institutions | 93.70 % | ||||
| Number Of Shares Shorted | 7.64 M | ||||
| Price To Earning | (12.01) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.Note that the Guardant Health information on this page should be used as a complementary analysis to other Guardant Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Guardant Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 5.036 | Quarterly Revenue Growth 0.222 | Return On Assets (0.18) | Return On Equity (4.38) |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.